FOLD - Amicus Therapeutics GAAP EPS of -$0.92 misses by $0.16 revenue of $305.51M misses by $1.21M
Amicus Therapeutics press release (NASDAQ:FOLD): FY GAAP EPS of -$0.92 misses by $0.16. Revenue of $305.51M (+17.1% Y/Y) misses by $1.21M. Outlook: For the full-year 2022, the Company anticipates total Galafold revenue of at least $350 million to $365 million. Non-GAAP operating expense guidance for the full-year 2022 is $470 million to $485 million.
For further details see:
Amicus Therapeutics GAAP EPS of -$0.92 misses by $0.16, revenue of $305.51M misses by $1.21M